靈北公司是一家專注于精神及神經系統領域的全球性制藥公司。靈北擁有超過70年在神經科學領域的前沿的專業研究經驗。我們的關注疾病領域為抑郁癥、精神分裂癥、阿爾茨海默病及帕金森病。<\/p> \n

我們在全球范圍內擁有員工5000余人，業務遍及全球55個國家，擁有從研究、開發、生產、到市場推廣完整的醫藥價值鏈。我們的新產品有很多已進入后期開發，產品遍及全球100多個國家。<\/p> \n

90年代末期，靈北通過與合作伙伴合作的方式進入中國市場。靈北的目標和愿景是以不斷改善患者的生命質量為己任，為成為中國精神及神經疾病領域的領導者而不懈努力。<\/p> \n

作為一家專注于精神和神經系統疾病領域的跨國制藥企業，在中國處方治療抑郁癥的藥物中，靈北公司占據了約23%的市場份額。靈北已上市的藥物黛力新^{®<\/sup>、喜普妙^{®<\/sup>、來士普^{®<\/sup>等很好地服務了中國眾多抑郁癥患者。在治療阿爾茨海默病方面，靈北推出的易倍申^{®<\/sup>市場份額達到了24%，幫助了成千上萬的中國患者及看護。<\/p> \n}}}}

靈北創造的價值來自于我們發現、培育和傳播的創新治療方案。靈北是丹麥在研發方面投入最大的公司之一。通過將治療帕金森病藥物安齊來^{®<\/sup>和治療抑郁癥藥物心達悅^{®<\/sup>帶入中國，靈北將給更多中國神經精神疾病患者帶來新曙光。<\/p> \n}}

靈北致力于精神和神經系統領域的知識普及和教育。2008年靈北學院正式進入中國以來，從最初覆蓋北京、上海、廣州等大城市十幾家醫院，到全國幾十個大中城市的兩百多家醫院，發起了一系列關鍵醫學教育活動：癡呆&認知研討班，WPA -- 靈北學院中國抑郁教育項目，骨干青年醫師培訓項目。我們的目標是使靈北成為改善中國CNS患者生命質量的領導聲音。<\/p> \n

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
<optgroup id="kgssg"></optgroup>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区

參考文獻<\/span><\/p> <\/td> \n <\/tr> \n

^{[1]<\/sup> World Health Organization. Depression and other common mental disorders: global health estimates. WHO\/MSD\/MER\/2017.2: 21<\/span><\/p> <\/td> \n <\/tr> \n}

http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/254610\/WHO-MSD-MER-2017.2-eng.pdf<\/a> <\/span><\/p> <\/td> \n <\/tr> \n

^{[2]<\/sup> World Health Organization. Depression and other common mental disorders: global health estimates. WHO\/MSD\/MER\/2017.2: 21<\/span><\/p> <\/td> \n <\/tr> \n}

http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/254610\/WHO-MSD-MER-2017.2-eng.pdf<\/a> <\/span><\/p> <\/td> \n <\/tr> \n

^{[3]<\/sup> From the survey report “Impact of Depression at Work” launched in 2014<\/span><\/p> <\/td> \n <\/tr> \n}

^{[4] <\/sup>https:\/\/rd.springer.com\/article\/10.1007\/S00127-006-0151-2<\/a> <\/span><\/p> <\/td> \n <\/tr> \n}

^{[5]<\/sup> Lee S, Tsang A, et al. The epidemiology of depression in metropolitan China. Psychol Med 2009;39(5):735-747) (22.7% sought treatment) <\/span><\/p> <\/td> \n <\/tr> \n}

^{[6]<\/sup> http:\/\/www.who.int\/mediacentre\/news\/releases\/2016\/depression-anxiety-treatment\/en\/<\/a> <\/span><\/p> <\/td> \n <\/tr> \n}

^{[7]<\/sup> The 2015-2020 National Mental Health Workplan of the People's Republic of China<\/span><\/p> <\/td> \n <\/tr> \n}

^{[8]<\/sup> Hou Z et al. Neruosci Bull. 2016 Aug; 32(4): 389-397<\/span><\/p> <\/td> \n <\/tr> \n}

^{[9]<\/sup> Rush AJ et al. Am J Psychiatry 2006; 163(11):1905–1917<\/span><\/p> <\/td> \n <\/tr> \n}

^{[10]<\/sup> Mclntyre&O” Donovan. CanJ Psychiatry 2004; 49(3)<\/span><\/p> <\/td> \n <\/tr> \n}

^{[11]<\/sup> Zimmerman et al. J Clin Psychiatry 2017;73(6):790-795<\/span><\/p> <\/td> \n <\/tr> \n}

^{[12]<\/sup> Zimmerman M, et al. Remission in depressed outpatients: more than just symptom resolution? J Psychiatr Res. 2008 Aug;42(10):797-801. <\/span><\/p> <\/td> \n <\/tr> \n}

^{[13]<\/sup> Zimmerman M., et al. Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission? J Clin Psychiatry. 2012 Jun;73(6):790-5.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n}
圖片 - https:\/\/photos.prnasia.com\/prnh\/20180424\/2111889-1-a<\/a>
圖片 - https:\/\/photos.prnasia.com\/prnh\/20180424\/2111889-1-b<\/a>
圖片 - https:\/\/photos.prnasia.com\/prnh\/20180424\/2111889-1-c<\/a> <\/p>"]; $("#dvExtra").html(content_array[0]);})();
<center id="kgssg"></center>